Rituximab in the treatment of peripheral neuropathy associated with monoclonal gammopathy

Author: Živković, Saša A

Source: Expert Review of Neurotherapeutics, Volume 6, Number 9, September 2006 , pp. 1267-1274(8)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Peripheral neuropathy associated with immunoglobulin (Ig)M gammopathy and anti-myelin-associated glycoprotein antibodies is frequently treatment-resistant and different treatment regimens carry substantial toxicity and side effects. More recently, the chimeric anti-CD20 monoclonal antibody rituximab has shown benefits in the treatment of peripheral neuropathy associated with IgM gammopathy with a favorable side-effect profile. There are no published reports of its use in the treatment of neuropathy associated with IgG and IgA gammopathies. Rituximab is usually given at 375 mg/m² intravenously with four weekly doses that may be repeated after 6-12 months. Large controlled studies are still pending but rituximab is an exciting and promising treatment offering another option in the treatment of peripheral neuropathy associated with IgM monoclonal gammopathy.

Keywords: anti-MAG antibody; CD20; immunoglobulinM; monoclonal gammopathy; peripheral neuropathy; rituximab

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14737175.6.9.1267

Publication date: 2006-09-01

More about this publication?

Expert Review of Neurotherapeutics provides expert commentary on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer's and Parkinson's.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites